RxDoctor Payments Data

Peter Nechay, MD

Cardiovascular Disease · Kokomo, INNPI 1831168525

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 49 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$196
  • Boston Scientific$145
  • Esperion Therapeutics, Inc.$125
  • Novartis$104
  • Amarin Pharma, Inc.$84
  • E.r. Squibb & Sons, L.L.C.$67
  • plus $305 from 11 others

What the payments were for

  • Food & beverage$1,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,026 in reported general payments places this provider in the 30th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$141,325
Medicare patients
917
Services billed
1,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban833$1,081,956
XareltoRivaroxaban135$182,142
EntrestoSacubitril/Valsartan117$168,830
MultaqDronedarone Hcl59$114,548
Repatha SureclickEvolocumab95$110,025
JardianceEmpagliflozin18$20,633
Praluent PenAlirocumab14$16,428
Ranolazine ErRanolazine63$11,778
Rosuvastatin Calcium721$10,466
Diltiazem 24hr Er (Cd)Diltiazem Hcl282$8,494
Metoprolol Succinate547$8,234
Atorvastatin Calcium445$5,987
Nebivolol Hcl122$5,978
Carvedilol467$5,577
Potassium Chloride353$5,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$1,081,956833 claims
Johnson & JohnsonXarelto$196$182,142135 claims
NovartisEntresto$104$168,830117 claims
Sanofi-aventis U.S. LLCMultaq$61$114,54859 claims
Boehringer IngelheimJardiance$12$20,63318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →